16,284 resources
Start Prev Rows 8400 - 8600 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date |
|---|---|---|---|---|---|---|---|
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.35 | Aspirin or Clopidogrel | active | 2024-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.39 | Cardiac Rehabilitation | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.4 | Hypothyroidism | active | 2021-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.40 | Cardiac Rehabilitation | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.43 | SGLT2 Ingredients | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.44 | MRA Ingredients | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.49 | Minnesota Living with Heart Failure Questionnaire | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.5 | Hypothyroidism | active | 2024-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.50 | Kansas City Cardiomyopathy Questionnaire | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.51 | Cardiac Pacer | active | 2021-11 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.52 | Cardiac Pacer | active | 2025-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.53 | Cardiac Pacer | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.54 | Heart Transplant Complications | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.55 | Heart Transplant Complications | active | 2025-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.56 | Heart Transplant Complications | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.57 | Left Ventricular Assist Device Complications | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.58 | Left Ventricular Assist Device Complications | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.59 | Left Ventricular Assist Device Placement | active | 2023-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.6 | Hypothyroidism | active | 2021-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.60 | Left Ventricular Assist Device Placement | active | 2023-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.61 | Left Ventricular Assist Device Placement | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.62 | Left Ventricular Assist Device Placement | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.63 | Heart Transplant | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.65 | Cardiac Pacer | active | 2022-11 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.66 | Diastolic Heart Failure | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.67 | Diastolic Heart Failure | active | 2023-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.68 | Diastolic Heart Failure | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.69 | Allergy to SGLT2 Inhibitors | active | 2023-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.7 | Anorexia Nervosa | active | 2023-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.70 | Intolerance to SGLT2 Inhibitors | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.71 | Intolerance to MRA Therapy | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.72 | ARNI Ingredient | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.73 | Mitral Stenosis | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.74 | Mitral Stenosis | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.75 | Mitral Stenosis | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.76 | Mechanical Prosthetic Heart Valve | active | 2022-11 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.77 | Mechanical Prosthetic Heart Valve | active | 2025-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.78 | Mechanical Prosthetic Heart Valve | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.79 | Mechanical Prosthetic Heart Valve in Situ | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.8 | Anorexia Nervosa | active | 2021-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.82 | Systolic Heart Failure | active | 2023-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.83 | Systolic Heart Failure | active | 2023-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.84 | Systolic Heart Failure | active | 2023-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.85 | Carotid Intervention | active | 2023-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.86 | Serum Creatinine | active | 2023-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.87 | Urine Creatinine | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.88 | Urine Albumin | active | 2023-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.9 | Anorexia Nervosa | active | 2021-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.90 | Non Steroidal Mineralcorticoid Receptor Antagonist | active | 2024-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.91 | Glucagon like peptide 1 medications | active | 2024-11 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1178.96 | AHA GWTG Long COVID19 | active | 2024-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.1 | Wound internal item and/or body structure visible value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.11 | Wound exudate appearance value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.12 | Wound exudate color value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.13 | Exudate odor value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.16 | Skin temperature value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.17 | Skin color enumerated value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.18 | Skin turgor value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.19 | Skin and mucous membrane integrity value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.2 | Periwound condition value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.20 | Skin moisture value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.3 | Wound Type Etiology value set | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.4 | Wound episode value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.6 | Wound bed appearance value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.60 | Wound type reference set | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.7 | Wound bed color value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.74 | Nonverbal pain indicators reference set | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.76 | Pain associated signs and symptoms reference set | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.77 | Pain body location reference set | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.8 | Wound edge description value set (foundation metadata concept) | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.80 | Pain quality reference set | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.81 | Pain speed of onset reference set | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1181.9 | Presence absence value set (foundation metadata concept) | active | 2018-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1186.1 | Common drug substances for allergy and intolerance documentation | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1186.2 | Common drug classes for allergy and intolerance documentation | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1186.3 | Common dietary substances for allergy and intolerance documentation | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1186.4 | Common environmental substances for allergy and intolerance documentation | active | 2024-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.10 | NHSNCriterionOfDiagnosisCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.11 | NHSNCriterionOfDiagnosisCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.12 | NHSNInfectionConditionCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.13 | NHSNInfectionConditionCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.14 | NHSNInfectionTypeCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.15 | NHSNInfectionTypeCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.16 | NHSNInfectionFirstReportedSource(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.17 | NHSNInfectionFirstReportedSource(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.18 | NHSNLOS/MENDischargeDisposition(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.19 | NHSNLOS/MENDischargeDisposition(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.20 | NHSNPopulationSummaryReportTypeCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.21 | NHSNPopulationSummaryReportTypeCode(LOINC) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.22 | NHSNSameDayOutcomeMeasure(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.23 | NHSNSameDayOutcomeMeasure(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.24 | NHSNSignificantPathogenCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.25 | NHSNSignificantPathogenCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.26 | NHSNSpinalFusionApproachCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.27 | NHSNSpinalFusionApproachCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.28 | NHSNVascularAccessTypeCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.29 | NHSNVascularAccessTypeCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.30 | NHSNVascularSpecimenCollectionSite(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.31 | NHSNVascularSpecimenCollectionSite(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.38 | Blood Glucose Laboratory and Point of Care Tests | active | 2023-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.6 | NHSNPathogenCodeARO | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.63 | Bacterial and Fungal Blood Culture Tests | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.7 | NHSNRoleOfPerformerCode(CDCNHSN) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.74 | Enteral Medication Route | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.75 | Intravenous Medication Route | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.79 | Fidaxomicin, Vancomycin, and Metronidazole | active | 2022-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.8 | NHSNRoleOfPerformerCode(SNOMEDCT) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.85 | Baloxavir | active | 2023-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.86 | Peramivir | active | 2023-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.87 | Zanamivir | active | 2023-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.88 | Digestive, Intramuscular, Intravenous Route of Administration | active | 2023-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.9 | NHSNRoleOfPerformerCode(HealthCareProviderTaxonomy) | active | 2020-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.90 | NHSN LTC AU Antimicrobial Agents | active | 2024-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.91 | Long Term Care Discharge Disposition | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.94 | NHSNNeurogenicBladder | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1190.95 | NHSNSpinalCordInjury | active | 2025-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.147 | SCIP Major Surgical Procedure | active | 2019-06 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3483 | Financial Insecurity Screening Assessments Questions | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3484 | Food Insecurity Screening Assessments Questions | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3485 | Health Literacy Screening Assessments Questions | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3486 | Homelessness Screening Assessments Questions | active | 2023-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3487 | Housing Instability Screening Assessments Questions | active | 2023-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3488 | Less Than High School Education Screening Assessments Questions | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3519 | Health Insurance Coverage Status Screening Assessments And Questions | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.3520 | Inadequate Housing Screening Assessments And Questions | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.393 | Hypoglycemics Severe Hypoglycemia | active | 2024-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.394 | Hypoglycemics Treatment Medications | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.4448 | Lidocaine | active | 2024-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.491 | Medium Dose ICS Formoterol Preparations | active | 2021-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.495 | ICS LABA LAMA Preparations | active | 2021-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1196.788 | Social Determinants of Health Conditions | active | 2024-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.15 | General Surgery | active | 2020-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.17 | Coagulation Disorder Conditions | active | 2020-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.19 | Anticoagulant Medications | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.20 | Anticoagulant Medications, Oral | active | 2024-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.21 | Anticoagulant Medications, Injection | active | 2024-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.28 | Active Bleeding | active | 2020-11 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.29 | Fall Risk Increasing Drugs (FRIDs) | active | 2021-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.30 | Fall Risk Factors | active | 2021-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.32 | Total Hip Arthroplasty Surgery | active | 2021-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.33 | Total Knee Arthroplasty Surgery | active | 2021-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.46 | Opioid Medications | active | 2021-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.47 | Imaging Related to VTE | active | 2023-01 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.48 | Anticoagulant Medication | active | 2024-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.49 | VTE Diagnoses | active | 2025-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.50 | Bisphosphonate Therapy | active | 2022-02 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.51 | VTE Symptoms | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.52 | Oncology Critical Care Units | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.53 | Provider Types | active | 2022-05 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.56 | FOBT_Lab | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.58 | Screening Mammogram (CPT) | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.59 | Screening Mammogram (LOINC) | active | 2024-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.60 | Screening Mammogram (SNOMEDCT) | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.61 | Screening Mammogram (Grouping) | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.62 | Diagnostic Mammography (CPT) | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.63 | Diagnostic Mammography (LOINC) | active | 2024-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.64 | Diagnostic Mammography (SNOMEDCT) | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.65 | Diagnostic Mammography | active | 2024-08 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.66 | Breast Cancer Biopsy and Surgical Excision | active | 2024-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.67 | BI_RADS Categories 0, 4, and 5 | active | 2024-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1206.68 | BI_RADS Categories 1, 2, and 3 | active | 2024-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.101 | Local Anesthetics | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.102 | Ophthalmic Epinephrines | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.103 | Inhaled Epinephrines | active | 2023-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.104 | Clopidogrels | active | 2023-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.105 | Cytochrome P450 2C19 inhibitors | active | 2023-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.107 | Aspirin Ingredient and Risk of GI Bleeding | active | 2023-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.109 | Oral Anticoagulant Ingredients and Risk of GI Bleeding | active | 2023-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.112 | PPI and Risk of GI Bleeding | active | 2023-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.113 | Antiplatelet Ingredients and Risk of GI Bleeding | active | 2023-12 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.115 | Kratom containing compounds | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.117 | Clopidogrel Ingredients and Risk of GI Bleeding | active | 2024-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.121 | Gastrointestinal bleeding episode and Risk of GI Bleeding 1 | active | 2024-10 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.122 | Gastrointestinal bleeding episode and Risk of GI Bleeding 2 | active | 2024-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.123 | Gastrointestinal bleeding episode and Risk of GI Bleeding | active | 2024-09 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1213.24 | Oxycodones | active | 2024-07 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.1 | Bronchiectasis Disorder SNOMED | active | 2020-04 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.10 | Interstitial Lung Disease ICD10CM | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.100 | Occupational Therapy Procedure HCPCS | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.101 | Occupational Therapy Procedure | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.102 | Speech Language Therapy Procedure HCPCS | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.103 | Speech Language Therapy Procedure | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.104 | Home Health Procedure | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.105 | Intermittent Skilled Nursing Home Health Procedure | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.106 | pH, Hematocrit, Partial Pressure Carbon Dioxide, Partial Pressure Oxygen or Bicarbonate Laboratory Test for Breathing Assistance Device Evaluation Excluding Oxygen Saturation | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.107 | Breathing Test Procedure During Sleep | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.108 | Ambulance Transport Procedure | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.109 | Prefabricated Spinal Orthotic Device | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.11 | Interstitial Lung Disease SNOMEDCT | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.110 | Custom Fitted Spinal Orthotic Device | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.111 | Custom Fabricated Spinal Orthotic Device | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.112 | Orthotic Device Supply | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.113 | Spinal Orthotic Device or Supply | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.115 | Spine or Neck Disorder SNOMED CT | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.116 | Spine or Neck Disorder ICD10CM | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.117 | Spine or Neck Disorder | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.118 | Total Electric Hospital Bed Supply | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.119 | Hypoventilation Disorder SNOMEDCT | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.12 | Interstitial Lung Disease | active | 2022-03 | ||
| us.nlm.vsac | R4 | ValueSet/2.16.840.1.113762.1.4.1219.120 | Hypoventilation Disorder ICD10CM | active | 2022-03 |
FHIR